Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer Sarah SammonsNoah S. KornblumKimberly L. Blackwell Review Article Open access 22 August 2018 Pages: 1 - 12
Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer Sarah SammonsNoah S. KornblumKimberly L. Blackwell Correction 08 December 2018 Pages: 13 - 13
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG) Albert FontRaquel LuqueJosé Ángel Arranz Review Article 29 January 2019 Pages: 15 - 32
Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx Ilya TsimafeyeuPavel BorisovGennady Bratslavsky Original Research Article 03 January 2019 Pages: 33 - 38
BI 853520, a FAK-Simile of Prior FAK Inhibitors? Rachael Chang LeeHui K. Gan Commentary 07 March 2019 Pages: 39 - 41
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies Maja J. A. de JongeNeeltje SteeghsLillian L. Siu Original Research Article Open access 11 February 2019 Pages: 43 - 55
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors Toshihiko DoiJames Chih-Hsin YangChia-Chi Lin Original Research Article Open access 06 February 2019 Pages: 57 - 65
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520 Remy B. VerheijenDiane A. J. van der BiessenMartijn P. Lolkema Original Research Article Open access 11 February 2019 Pages: 67 - 74
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib Maximilian J. HochmairAnna BuderMartin Filipits Original Research Article Open access 12 December 2018 Pages: 75 - 83
Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry Li Chia ChongAmanda Rose TownsendTimothy Jay Price Original Research Article 18 January 2019 Pages: 85 - 91
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy Zhuanglin LiMingxue WangChangjiang Huang Original Research Article 11 January 2019 Pages: 93 - 105
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma Emma D. Deeks Adis Drug Evaluation 14 February 2019 Pages: 107 - 113
